N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands
    1.
    发明申请
    N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands 失效
    N-(1,2,3,4-四氢萘-1-基)-4-苯基-1-哌嗪烷基酰胺衍生物及其作为5-HT 7受体配体的治疗用途

    公开(公告)号:US20070117811A1

    公开(公告)日:2007-05-24

    申请号:US11283608

    申请日:2005-11-18

    IPC分类号: A61K31/496 C07D241/04

    摘要: A series of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides was prepared and their affinity for serotonin 5-HT7, 5-HT1A, and 5-HT2A receptors was measured using in vitro binding assays. In relation to 5-HT7 receptor affinity, receptor binding studies indicated that: (i) the optimal alkyl chain length was five methylenes; (ii) an unsubstituted 1,2,3,4-tetrahydronaphthalenyl nucleus was selected for further substitutions; and (iii) the substitution pattern of the aryl ring linked to the piperazine ring played a significant role. Several compound with high affinity for 5-HT7 receptors were identified. Among them, 4-(2-methoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (28), 4-(2-acetylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (34), 4-(2-methylthiophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (44), 4-(2-hydroxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (46), 4-(2-methylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (49) were assayed for the 5-HT7 receptor mediated relaxation of substance P-induced guinea-pig ileum contraction. Compounds 28, 44, and 49 behaved as full agonists, compound 34 as a partial agonist, whereas derivative 46 acted as an antagonist.

    摘要翻译: 制备了一系列N-(1,2,3,4-四氢萘-1-基)-4-芳基-1-哌嗪烷基酰胺,并且它们对5-羟色胺5-HT 7 5-HT 使用体外结合测定法测量1A和/或5-HT 2A受体。 关于5-HT 7受体亲和力,受体结合研究表明:(i)最佳烷基链长度为5个亚甲基; (ii)选择未取代的1,2,3,4-四氢萘基核进一步取代; 和(iii)与哌嗪环连接的芳环的取代模式发挥了重要作用。 鉴定了对5-HT 7受体具有高亲和力的几种化合物。 其中,4-(2-甲氧基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(28),4-(2-乙酰基苯基)-N-(1,2 ,3,4-四氢萘-1-基)-1-哌嗪己酰胺(34),4-(2-甲硫基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(44 ),4-(2-羟基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(46),4-(2-甲基苯基)-N-(1,2, 3,4-二氢萘-1-基)-1-哌嗪己酰胺(49)测定5-HT 7受体介导的物质P诱导的豚鼠回肠收缩的松弛。 化合物28,44和49表现为完全激动剂,化合物34作为部分激动剂,而衍生物46用作拮抗剂。

    N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands
    2.
    发明授权
    N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-phenyl-1-piperazinealkylamide derivatives, and therapeutic use thereof as 5-HT7 receptor ligands 失效
    N-(1,2,3,4-四氢萘-1-基)-4-苯基-1-哌嗪烷基酰胺衍生物及其作为5-HT 7受体配体的治疗用途

    公开(公告)号:US07488730B2

    公开(公告)日:2009-02-10

    申请号:US11283608

    申请日:2005-11-18

    IPC分类号: A61K31/495 C07D295/15

    摘要: A series of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides was prepared and their affinity for serotonin 5-HT7, 5-HT1A, and 5-HT2A receptors was measured using in vitro binding assays. In relation to 5-HT7 receptor affinity, receptor binding studies indicated that: (i) the optimal alkyl chain length was five methylenes; (ii) an unsubstituted 1,2,3,4-tetrahydronaphthalenyl nucleus was selected for further substitutions; and (iii) the substitution pattern of the aryl ring linked to the piperazine ring played a significant role. Several compound with high affinity for 5-HT7 receptors were identified. Among them, 4-(2-methoxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (28), 4-(2-acetylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (34), 4-(2-methylthiophenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (44), 4-(2-hydroxyphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (46), 4-(2-methylphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide (49) were assayed for the 5-HT7 receptor mediated relaxation of substance P-induced guinea-pig ileum contraction. Compounds 28, 44, and 49 behaved as full agonists, compound 34 as a partial agonist, whereas derivative 46 acted as an antagonist.

    摘要翻译: 制备了一系列N-(1,2,3,4-四氢萘-1-基)-4-芳基-1-哌嗪烷基酰胺,并测定了它们对5-羟色胺5-HT7,5-HT1A和5-HT2A受体的亲和性 使用体外结合测定。 关于5-HT7受体亲和力,受体结合研究表明:(i)最佳烷基链长度为五个亚甲基; (ii)选择未取代的1,2,3,4-四氢萘基核进一步取代; 和(iii)与哌嗪环连接的芳环的取代模式发挥了重要作用。 鉴定了几种对5-HT7受体具有高亲和力的化合物。 其中,4-(2-甲氧基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(28),4-(2-乙酰基苯基)-N-(1,2 ,3,4-四氢萘-1-基)-1-哌嗪己酰胺(34),4-(2-甲硫基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(44 ),4-(2-羟基苯基)-N-(1,2,3,4-四氢萘-1-基)-1-哌嗪己酰胺(46),4-(2-甲基苯基)-N-(1,2, 3,4-二氢萘-1-基)-1-哌嗪六酰胺(49)测定了5-HT7受体介导的物质P诱导的豚鼠回肠收缩的松弛。 化合物28,44和49表现为完全激动剂,化合物34作为部分激动剂,而衍生物46用作拮抗剂。